More Stories

Informist, Monday, Feb. 2, 2026

 

Please click here to read all liners published on this story

--Glenmark Pharma: India going to be big growth mkt for co in next 2-3 yrs 
--Glenmark Pharma: Working on Ryaltris launch in China, Brazil 
--Glenmark Pharma: Nasal Spray Ryaltris has potential of $2 mln-$250 mln 
--Glenmark Pharma: Net cash reserves at INR 6 bln as on Dec 31 
--Glenmark Pharma: FY27 capex seen around INR 8 billion 
--Glenmark Pharma: To fully commercialise Aumolertinib in all mkts by FY28 
--Glenmark Pharma: Capex spending so far INR 7.15 bln in FY26 
--Glenmark Pharma: Expect double-digit growth in Europe for FY27 
--Glenmark Pharma: See EBITDA margin at 23% sustainable going forward 
--Glenmark Pharma: Nasal spray Ryaltris likely to generate $1 mln a year 
--Glenmark Pharma: To begin commercial ops at Monroe unit in Q4 
--Glenmark Pharma: Positive regulatory outcome on Monroe to boost US ops 
--Glenmark Pharma: 7-8 new pdts to drive exciting growth in next 5 yrs 
--Glenmark Pharma: Lined up good product launches in US in Q4 
--CONTEXT: Glenmark Pharma mgmt comment in a post-earnings analysts concall 
--Glenmark Pharma: Winlevi saw uptick in sales in Europe 
--Glenmark Pharma: Plan to file three ANDAs in Q4 in US
 

 

By Narayana Krishna and Adhithya Aji

 

HYDERABAD/MUMBAI - Glenmark Pharmaceuticals Ltd. expects seven-eight new and innovative products lined up for launch to drive growth for the company in the next five years, the company's management said in a post-earnings conference call on Monday.

 

Glenmark is expecting its nasal spray product, Ryaltris, used to treat symptoms like sneezing, runny nose, congestion, and itchy watery eyes, to generate $100 million a year from 2026-27 (Apr-Mar) and has the potential to generate up to $200 million-$250 million once the product is expanded to all markets.

 

On Friday, Glenmark reported a consolidated net profit of INR 4.03 billion for the December quarter, up 16% on year. Its revenue from operations for the quarter rose 15% on year to INR 39.01 billion.

 

A positive outcome from the US Food and Drug Administration for the company's facility at Monroe in North Carolina in the US will be a significant boost for its US growth, besides the new innovative launch pipeline, Glenmark Pharma said. Products such as Ryaltris, along with cancer drugs Aumolertinib and Winelvi, are expected to drive growth going forward, the company said.

 

"So, in summary, the next five years continue to remain pretty exciting for Glenmark in terms of growth performance across all the parameters. We continue to move up the value chain, especially with our innovative franchise over the next five years, through these seven eight launches, which will clearly define the company and the future as we go forward," the company's management said.

 

Glenmark Pharma's Monroe facility makes sterile injectables, which are high-margin products. The company got an establishment inspection report recently with a voluntary action indicated tag, which gives Glenmark Pharma a boost to begin commercial operations in the March quarter. The company plans to expedite the new product application filings from this site and has lined up high-value innovative product launches in the US in the next one-two years, the management said. In the March quarter, Glenmark plans to file at least three new drug applications with US FDA for approval. For Aumolertinib, for which the company is in a pact with Hansoh Pharma, it expects a launch across all markets by FY28. 

Glenmark is pinning hopes on its key innovative product Ryaltris, and working on expanding the product into new markets such as China and Brazil. The company received the approval of the regulator in China for the drug in November. The company already launched the product in India and the US in 2022 and is getting significant contribution to its growth. 

Glenmark Pharma expects double digit-growth in Europe in FY27, led by new product launches and ramping up of existing products. The company said its acne drug Winlevi has seen an uptick in sales in Europe. From India too, the company expects significant contribution to the overall growth for the next two-three years.

Glenmark Pharma's management said its earnings before interest, tax, depreciation, and amortisation margin is seen around 23% on a sustainable basis going forward. Some of the innovative products may boost the margin, though in the medium term, the company is confident of current margin levels. The company recorded capital expenditure of INR 7.15 billion in Apr-Dec. The capital expenditure in FY27 is seen around INR 8 billion, the company said. Glenmark Pharma had net cash reserves of INR 6 billion as on Dec. 31.

At 1010 IST, shares of Glenmark Pharma were trading at INR 1,898 on the National Stock Exchange, down 2.2%.  End

 

US$1 = INR 91.73

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Edited by Avishek Dutta

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.